A prospective randomized comparison of oral terbutaline and magnesium oxide for the maintenance of tocolysis

Am J Obstet Gynecol. 1990 Sep;163(3):879-82. doi: 10.1016/0002-9378(90)91087-s.

Abstract

We compared oral magnesium oxide with oral terbutaline sulfate in a prospective, randomized manner to determine efficacy and side effects. Preterm labor patients whose labor was arrested with parenteral tocolysis were randomized to oral tocolysis with either magnesium oxide, 200 mg every 3 to 4 hours (n = 23), or terbutaline, 2.5 to 5 mg every 3 to 4 hours (n = 27). The number of patients who were delivered of infants before 36 weeks' gestation was similar between groups (18.5% receiving terbutaline versus 17.4% receiving magnesium). At least one side effect occurred in 81.5% of patients in the terbutaline group and 47.8% in the magnesium group (p less than 0.01). Finally, the cost for 1 day of magnesium (20 cents) is approximately one third the cost of terbutaline (56 cents). These data suggest that oral magnesium oxide is as effective as terbutaline for the maintenance of tocolysis, with fewer side effects and at a lower cost.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Female
  • Humans
  • Magnesium Oxide / adverse effects
  • Magnesium Oxide / therapeutic use*
  • Obstetric Labor, Premature / prevention & control*
  • Pregnancy
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Terbutaline / adverse effects
  • Terbutaline / therapeutic use*
  • Tocolysis*

Substances

  • Magnesium Oxide
  • Terbutaline